Plasma Sphingomyelins as Biomarkers for Diabetic Retinal Neurodegeneration: The Maastricht Study
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Authors
- Frank van de Baan (ORCID: https://orcid.org/0000-0002-8085-0245)
- Tos T. J. M. Berendschot (ORCID: https://orcid.org/0000-0002-8101-939X)
- Marleen M. J. van Greevenbroek (ORCID: https://orcid.org/0000-0002-2989-1631)
- Siddhita Nare (ORCID: https://orcid.org/0000-0003-3754-1313)
- Sara Mokhtar (ORCID: https://orcid.org/0000-0003-4209-0502)
- Birke J. Benedikter (ORCID: https://orcid.org/0000-0002-1103-2484)
- Carroll A.B. Webers (ORCID: https://orcid.org/0000-0001-5605-740X)
- Govindasamy Kumaramanickavel
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- Sorbonne Paris Cité (FR)
- Fondation de Rothschild (FR)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1016/j.xops.2025.100870
- Citations
- 1
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Sanofi
- Health Foundation Limburg
- Novo Nordisk
- Stichting De Weijerhorst
- European Regional Development Fund
- CARIM School for Cardiovascular Diseases, Universiteit Maastricht
- Care and Public Health Research Institute, Universiteit Maastricht
- NUTRIM School of Nutrition and Translational Research in Metabolism
- Cilag